These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 16386540)

  • 1. Effect of calcineurin inhibitors on low-density lipoprotein oxidation.
    Cofan F; Cofan M; Campos B; Guerra R; Campistol JM; Oppenheimer F
    Transplant Proc; 2005 Nov; 37(9):3791-3. PubMed ID: 16386540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of cyclosporin and tacrolimus on lipoprotein oxidation after renal transplantation].
    Martínez Castelao A; Ramos R; Serón D; Gil-Vernet S; Fiol C; Gómez-Gerique N; Yzaguirre MT; Hurtado I; Sabaté I; Alsina J; Grinyó JM
    Nefrologia; 2002; 22(4):364-9. PubMed ID: 12369128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications?
    Badiou S; Garrigue V; Dupuy AM; Chong G; Cristol JP; Mourad G
    Transplant Proc; 2006 Sep; 38(7):2314-6. PubMed ID: 16980076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-density lipoprotein oxidizability and the alteration of its fatty acid content in renal transplant recipients treated with cyclosporine/tacrolimus.
    Bakar F; Keven K; Dogru B; Aktan F; Erturk S; Tuzuner A; Erbay B; Nebioglu S
    Transplant Proc; 2009 Jun; 41(5):1630-3. PubMed ID: 19545695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
    White M; Haddad H; Leblanc MH; Giannetti N; Pflugfelder P; Davies R; Isaac D; Burton J; Chan M; Azevedo E; Howlett J; Ignaszewski A; Busque S; Cantarovich M; Ferguson R; Genest J; Ross H
    J Heart Lung Transplant; 2005 Jul; 24(7):798-809. PubMed ID: 15982605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters.
    Seymen P; Yildiz M; Türkmen MF; Titiz MI; Seymen HO
    Transplant Proc; 2009 Dec; 41(10):4181-3. PubMed ID: 20005364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
    Wissing KM; Unger P; Ghisdal L; Broeders N; Berkenboom G; Carpentier Y; Abramowicz D
    Transplantation; 2006 Sep; 82(6):771-8. PubMed ID: 17006324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrolimus, cyclosporine and plasma lipoproteins in renal transplant recipients.
    Venkiteswaran K; Sgoutas DS; Santanam N; Neylan JF
    Transpl Int; 2001 Dec; 14(6):405-10. PubMed ID: 11793038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Slowing progression of chronic allograft nephropathy by conversion from cyclosporin A to tacrolimus].
    Peng LK; Xie XB; Peng FH; Wang Y; Jiang Y; Lan GB; Fang CH; Nie MH
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):59-62. PubMed ID: 17344588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients.
    Manzarbeitia C; Reich DJ; Rothstein KD; Braitman LE; Levin S; Munoz SJ
    Liver Transpl; 2001 Feb; 7(2):93-9. PubMed ID: 11172391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
    Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
    Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid profiles in pediatric thoracic transplant recipients are determined by their immunosuppressive regimens.
    Law YM; Yim R; Agatisa P; Boyle GJ; Miller SA; Lawrence K; Webber SA
    J Heart Lung Transplant; 2006 Mar; 25(3):276-82. PubMed ID: 16507419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo oxidized low-density lipoprotein (ox-LDL) aopp and tas after kidney transplantation: a prospective, randomized one year study comparing cyclosporine A and tacrolimus based regiments.
    Zadrazil J; Horak P; Strebl P; Krejci K; Kajabova M; Schneiderka P; Zapletalova J; Galandakova A; Vostalova J; Vaverkova H
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Mar; 156(1):14-20. PubMed ID: 22580856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?
    Deleuze S; Garrigue V; Delmas S; Chong G; Swarcz I; Cristol JP; Mourad G
    Transplant Proc; 2006 Sep; 38(7):2311-3. PubMed ID: 16980075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal function in patients with cadaveric kidney transplants treated with tacrolimus or cyclosporine.
    Gonzalez Molina M; Morales JM; Marcen R; Campistol JM; Oppenheimer F; Serón D; Gil-Vernet S; Capdevila L; Andrés A; Lampreave I; Del Castillo D; Cabello M; Burgos D; Valdés F; Anaya F; Escuín F; Arias M; Pallardó L; Bustamante J
    Transplant Proc; 2007 Sep; 39(7):2167-9. PubMed ID: 17889126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus.
    Imamura R; Ichimaru N; Moriyama T; Shi Y; Namba Y; Nonomura N; Matsumiya K; Toki K; Takahara S; Okuyama A
    Clin Transplant; 2005 Oct; 19(5):616-21. PubMed ID: 16146552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved attainment of NKF classified lipid target levels after conversion from cyclosporine to tacrolimus in renal graft recipients.
    Pohanka E; Margreiter R; Sparacino V; Sperschneider H;
    Transplant Proc; 2005 May; 37(4):1874-6. PubMed ID: 15919490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile.
    Woodside KJ; Nichols SD; Hunter GC; Gugliuzza KK; Daller JA
    Transplant Proc; 2005 May; 37(4):1877-9. PubMed ID: 15919491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression.
    Martínez-Castelao A; Sarrias X; Bestard O; Gil-Vernet S; Serón D; Cruzado JM; Moreso F; Díez-Noguera A; Grinyó JM
    Transplant Proc; 2005 Nov; 37(9):3788-90. PubMed ID: 16386539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.